Key facts
- This page summarizes Blake Borgeson's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 10 Aug 2023, 17:33.
Blake Borgeson - 08 Aug 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Reporting relationship
- Director
- Issuer ticker
- RXRX
- Reported as of
- 08 Aug 2023
- Net transaction value
- -$198,283
- SEC form
- 4
- Accepted by SEC
- 10 Aug 2023, 17:33:24 UTC
- Prior SEC filing
- 13 Jul 2023
- Next SEC filing
- 24 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jonathan Golightly, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Blake Borgeson filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 10 Aug 2023.
Change
- Previous filing in this sequence was filed on 13 Jul 2023.
- Current net transaction value: -$198,283.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $159,848
- Shares
- -14,498
- Change %
- -0.19%
- Price
- $11.03
- Shares after
- 7,472,887
- Date
- 08 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
RXRX
transaction
Class A Common Stock
Sale
- Transaction value
- $38,436
- Shares
- -3,272
- Change %
- -0.04%
- Price
- $11.75
- Shares after
- 7,469,615
- Date
- 08 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 9, 2022.
Footnote F2
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.62 to $11.60 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
Footnote F3
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.62 to $11.93 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.